How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Geographic Atrophy Market
- By Disease Stage: Early Geographic Atrophy, Intermediate Geographic Atrophy, Advanced Geographic Atrophy
- By Treatment Modality: Pharmacological Therapies, Gene Therapy, Cell-Based Therapy, Laser Therapy, Supportive Care
- By Drug Class: Complement Inhibitors, Neuroprotective Agents, Anti-Inflammatory Agents, Antioxidants
- By Patient Demographics: Age Groups (50-64, 65-74, 75+), Gender, Genetic Risk Factors
- By Distribution Channel: Hospital Pharmacies, Specialty Clinics, Retail Pharmacies, Online Pharmacies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Early Geographic Atrophy leads By Disease Stage at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 293 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.176 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.184 →
Full report · locked preview
Everything inside the Geographic Atrophy Market report
A complete, evidence-based study - 12 chapters and 123 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Disease Stage 3
Treatment Modality 5
Drug Class 4
Patient Demographics 3
Distribution Channel 4
Companies profiled
Novartis AG
Apellis Pharmaceuticals Inc.
Genentech
Inc. (Roche)
Iveric Bio Inc.
Gyroscope Therapeutics Ltd.
Alcon Inc.
Regeneron Pharmaceuticals Inc.
Santen Pharmaceutical Co. Ltd.
Ophthotech Corporation
Kodiak Sciences Inc.
Chiesi Farmaceutici S.p.A.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Novartis AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Apellis Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Genentech
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Inc. (Roche)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Iveric Bio Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Gyroscope Therapeutics Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Alcon Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Regeneron Pharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Santen Pharmaceutical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Ophthotech Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Kodiak Sciences Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Chiesi Farmaceutici S.p.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Biogen Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Astellas Pharma Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Bayer AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Pfizer Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,236M by 2033 · 8.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Early Geographic Atrophy54.5
- Intermediate Geographic Atrophy27.4
- Advanced Geographic Atrophy18.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,280M → $2,469M · 8.6%
Europe$892.2M → $1,514M · 6.8%
Asia Pacific$814.6M → $1,457M · 7.5%
Latin America$504.3M → $877.4M · 7.2%
Middle East and Africa$387.9M → $772.5M · 9.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.062026
8.082027
8.082028
8.092029
8.112030
8.122031
8.132032
8.142033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Novartis AG19.9
- Apellis Pharmaceuticals Inc.14.2
- Genentech10.6
- Inc. (Roche)9.4
- Iveric Bio Inc.10.3
- Gyroscope Therapeutics Ltd.7.6
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Disease Stage31.2%
Treatment Modality14.8%
Drug Class15.7%
Patient Demographics18.5%
Distribution Channel19.8%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.8
- Europe21.4
- Asia Pacific20.6
- Latin America12.4
- Middle East and Africa10.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Novartis AG | 74 | 79 | 79 | 85 | 82 | 89 | 81 |
| Apellis Pharmaceuticals Inc. | 86 | 72 | 79 | 81 | 72 | 77 | 78 |
| Genentech | 70 | 72 | 76 | 73 | 76 | 85 | 75 |
| Inc. (Roche) | 68 | 79 | 79 | 82 | 78 | 79 | 78 |
| Iveric Bio Inc. | 70 | 61 | 74 | 68 | 76 | 75 | 71 |
| Gyroscope Therapeutics Ltd. | 46 | 70 | 46 | 55 | 57 | 60 | 56 |
| Alcon Inc. | 62 | 48 | 55 | 45 | 51 | 52 | 52 |
| Regeneron Pharmaceuticals Inc. | 35 | 39 | 39 | 40 | 45 | 49 | 41 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Novartis AG
- Apellis Pharmaceuticals Inc.
- Genentech
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Novartis AG | ✓ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Apellis Pharmaceuticals Inc. | ✓ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Genentech | ✓ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Inc. (Roche) | ◐ | ◐ | ✓ | ◐ | ✓ | ✓ |
| Iveric Bio Inc. | − | − | ◐ | ◐ | ◐ | ◐ |
| Gyroscope Therapeutics Ltd. | ◐ | ◐ | − | ◐ | − | ◐ |
| Alcon Inc. | − | − | − | − | − | ◐ |
| Regeneron Pharmaceuticals Inc. | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Novartis AG81
2Apellis Pharmaceuticals Inc.78
3Inc. (Roche)78
4Genentech75
5Iveric Bio Inc.71
6Gyroscope Therapeutics Ltd.56
7Alcon Inc.52
8Regeneron Pharmaceuticals Inc.41
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Novartis AGApellis Pharmaceuticals Inc.Inc. (Roche)
Challenger2
Strong scale, closing on the leaders.
GenentechIveric Bio Inc.
Niche3
Specialists in a single segment or region.
Gyroscope Therapeutics Ltd.Alcon Inc.Regeneron Pharmaceuticals Inc.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Disease Stage in North America, then scale across Geographic Atrophy Market — a $554M beachhead inside a $8.79B market.
Beachhead (SOM)$554Mobtainable near-term
Serviceable (SAM)$3.13Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Early Geographic Atrophy
Best fit — highest urgency & budget in Disease Stage.
Economic buyer81 fit
Intermediate Geographic Atrophy
Strong fit — clear ROI and a fast path to value.
End user70 fit
Advanced Geographic Atrophy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Disease Stage in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Treatment Modality & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Drug Class
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel28%
Digital / self-serve22%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Disease Stage leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Geographic Atrophy Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified21%
Evaluation11%
Closed-won6%
$9.9KCAC
$45KLTV
4.6:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Geographic Atrophy Market is a resilient opportunity — $7.75B by 2033, compounding at 4.9%.
TAM · 2025$5.27Btoday
TAM · 2033$7.75Bforecast
CAGR4.9%2027–2033
Cumulative$58.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.75BTotal addressable market
SAM$2.95BServiceable available market
SOM$607MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.9% CAGR
Demand compounds through 2033, outpacing GDP across Disease Stage.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Disease Stage moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.75BLarge & growingTAM by 2033 at 4.9% CAGR
$2.95BServiceable nowreachable with today’s model
$607MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.05BBear3.2% CAGR
$7.75BBase4.9% CAGR
$9.92BBull6.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Treatment Modality optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Geographic Atrophy Market — a $1.41B market by 2033. Plan: grow share from 6.3% to 13.7%.
Market size · 2033$1.41Btotal addressable
Market CAGR10.4%2027–2033
Target share13.7%from 6.3% today
Revenue ambition$193Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.3% | 13.7% | At risk |
| Revenue | $81M | $193M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 32.2% | 44.1% | On track |
| Customer retention | 86.3% | 93.7% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Disease Stage
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Treatment Modality capability
A defensible second engine — invest in Treatment Modality to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Disease Stage share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Treatment Modality
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $26M capacity & capability investment
- Greenlight bolt-on M&A in Treatment Modality
- Authorise North America expansion plan
- Fund R&D program for Disease Stage leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentBehind
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Geographic Atrophy Market conversation — a $6.98B market you can size, segment and defend in minutes.
Market size · 2033$6.98Btotal opportunity
Growth9.2%CAGR to 2033
Addressable buyers1,720+accounts in scope
Typical ROI4.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Disease Stage
Goal Grow share in Disease Stage
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.9×return on cost, year one
< 3 mopayback period
$91K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Novartis AGApellis Pharmaceuticals Inc.GenentechInc. (Roche)Iveric Bio Inc.Gyroscope Therapeutics Ltd.Alcon Inc.Regeneron Pharmaceuticals Inc.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Geographic Atrophy Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Geographic Atrophy Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Gentle Cell Dissociation Reagent Market
Market size, share, segmentation and regional forecast.
$850M market · 2025 base year
View reportGentamycin Sulfate Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportGentamicin Sulfate Injection Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportGentamicin Sulfate API Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportGenotyping Test Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportGenotyping Test Devices Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportGenotyping Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportGenotyping Arrays Market
Market size, share, segmentation and regional forecast.
$735M market · 2025 base year
View reportGenotoxicity Tests Market
Genotoxicity Tests Market is valued at USD 820 Million in 2025 and is expected to reach USD 1.1…
$820M market · 2025 base year
View reportGenotoxicity Testing Service Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportGenotoxicity Testing and Mutagenicity Testing Services Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportGenotoxic Impurities Analysis Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.